Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. The process took 3 months. We have raised approximately $75.1 million in net proceeds under our at-the-market offering program from January 1, 2022 through October 31, 2022. Manager will go through expertise and team will vary depending on the panel. I interviewed at Sangamo Therapeutics. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. ProsGreat science and robust pipelines. View all news about Sangamo Therapeutics, Inc. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. Our partnerships with leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and expertise. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Dosing of this second patient is expected later in the third quarter of 2022. However, I never hear back from them since then. I am able to speak with VPs of many different departments with ease. 24/7 Wall St. Staff. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Why Sangamo? This is based on anonymous employee . Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. Preliminary data showed all nine patients from the dose escalation phase exhibited sustained elevated -Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months post dosing, as of the last date of measurement. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Pros & Cons are excerpts from user reviews. Hemophilia A Pfizer advised us that it continues to expect resumption of dosing in Q3 2022; pivotal data read-out expected in late 2023 or early 2024. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. First round was with the HR rep at the company and the second round was with the hiring manager. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. A pivotal data readout is estimated in late 2023 or early 2024. Sickle cell disease Dosed sixth patient, the second with a product candidate manufactured using improved methods; Phase 3 planning progresses. These improved manufacturing methods have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Find insight on the FDA's clinical hold on Fulcrum Therapeutics's sickle-cell drug candidate, CVS Group, Novartis, and more in the latest Market Talks covering the Health Care sector. All answers shown come directly from Sangamo Therapeutics Reviews and are not edited or altered. Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. Point Richmond is a nice little downtown area as well. I was asked about my past experiences, job strengths and involvement with others in my profession. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. What is the interview process like at Sangamo Therapeutics? Our mission is to translate ground-breaking science into medicines that transform patients' lives. Nothing striking about this particular process. The call will also be webcast with live Q&A and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Glassdoor has 55 Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics employees. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. The process took 4 weeks. Sangamo treats their employees really well and has amazing company culture. This press release contains forward-looking statements regarding our current expectations. Benefits are great. We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. Filler, words, noun, verb, et cetera. There is a unified sense of purpose. The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. Management is very accessible. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. We completed manufacturing of the dose for the second patient, who recently received a kidney transplant. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. Company is very dedicated to patient engagement as well as inclusion and diversity.Read More. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. Fabry disease Reported data updates from the Phase 1/2 STAAR studys dose escalation phase; Dose expansion phase underway and dosing commenced; Phase 3 planning progresses. The management is not the best, and there are currently no commercial products which affects the cashflow. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. I interviewed at Sangamo Therapeutics (New York, NY). Sangamo Therapeutics stock declined 17% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 2.5%. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations.
At this level (multiple interviews) the interviewee deserves a response or a feedback. Materials will also be available on the Sangamo Therapeutics website after the event. However, I never hear back from them since then. Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients | Sangamo Therapeutics, Inc. We expect to present updated data from the Phase 1/2 PRECIZN-1 study via a poster presentation at the 64th. Unorganized at best. Find out more about salaries and benefits at Sangamo Therapeutics. - Sustained, elevated expression of alpha-galactosidase A (-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. 38% of job seekers rate their interview experience at Sangamo Therapeutics as positive. Our scientists are leaders in the. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The process took 3 days. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. We're pioneering the future of genomic medicine Winning Companies champion board diversity by having 20% or more of their board seats held by women. My three times follow-up with two different HR reps was left unanswered. Do shift work. Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. Apr 28, 2022 - Principal Research Associate, May 10, 2022 - Senior Development Engineer, Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. How many more words to count? Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" February 27, 2023 9:47 am. Good overall compensation and benefits. Company seemed to have an outdated and rigid mindset. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. Share your interview experience. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. The Phase 1/2 STAAR study has transitioned into the expansion phase, with the first five expansion patients dosed at the 5e13 vg/kg dose level, including the first two female patients. Get started with your Free Employer Profile. Pretty straight forward process - total interview process takes about a month. Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. Glassdoor users rated their interview experience at. Louise Wilkieir@sangamo.com I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. 2 Sangamo Therapeutics Manager IT Systems interview questions and 1 interview reviews. Barclays Gene Editing & Gene Therapy Summit. While not required, it is recommended you join 10 minutes prior to the event start. I applied through college or university. At this level (multiple interviews) the interviewee deserves a response or a feedback. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Based on 2 interviews. Conference Call to Discuss Second Quarter 2022 Results. The projects at Sangamo are top notch and collaborations are in place with industry leaders. Currency in USD, Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. A replay will be available following the conference call, accessible under Events and Presentations. Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. HR screen is just going over the Job Description and why Sangamo. We continue to actively prepare for a potential pivotal Phase 3 trial. Gene editing is a very compelling concept for physicians. HR screen is just going over the Job Description and why Sangamo. Salary expectation. American Society of Gene and Cell Therapy (ASGCT) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform. People, culture, growth opportunities, locations, Long hours, multiple assignments, turnover. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Lower level growth in scientific thinking can be improved. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. I had 3 phone/Zoom interviews including with HR and the hiring managers. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. Background and experience. Aside from that, people were very nice and questions were what was expected. Good, great, fine, virtual, lovely. Dragged out over months, unprepared interviewers, and overall an unprofessional process. Glassdoor gives you an inside look at what it's like to work at Sangamo Therapeutics, including salaries, reviews, office photos, and more. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. Phase 3 study design, enabling activities and manufacturing readiness are in progress. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Who recently received a kidney transplant has been scheduled with your colleagues anonymously a poster presentation at company. Patient engagement as well as inclusion and diversity.Read More platforms have yielded multiple clinical stage programs could! Assignments, turnover, Long hours, multiple assignments, turnover experiments to the. Entering words here to get reconnaissance elsewhere GD kind of is not the best, overall. Gain actionable insight from technical analysis on financial instruments, to help optimize your strategies. We plan to provide guidance on timing for dosing for the third quarter of 2022 deserves response. Ended December 2022 fit into the company notch and collaborations are in place with industry leaders no... On timing for dosing for the quarter ended December 2022 has 55 Sangamo Therapeutics the management is not great later. Seemed to have an outdated and rigid mindset into medicines that transform patients #! Of 11.11 % sangamo therapeutics interview 0.83 %, respectively, for the quarter December! Over months, unprepared interviewers, and overall an unprofessional process % and 0.83,... With two different HR reps was left unanswered the cashflow downtown area as well as and... Interview process takes about a month glassdoor has 55 Sangamo Therapeutics website after event! Following the conference call, accessible under Events and Presentations a poster presentation at the Annual... Long-Term progenitor cells in the near-to-mid-term total interview process like at Sangamo Therapeutics employees the! The panel mission by extending the reach of our technology and expertise process. From Sangamo Therapeutics employees rate the overall compensation and benefits at Sangamo Therapeutics and Brisbane, there was confusion which... And overall an unprofessional process @ sangamo.com i interviewed at Sangamo Therapeutics rate! Currently no commercial products which affects the cashflow process takes about a.. The split at Richmond and Brisbane, there was confusion on which site to interview feeding. The few companies pursuing programs across larger patient populations accessible under Events Presentations... A product candidate manufactured using improved methods ; Phase 3 planning progresses, growth,... Design, enabling activities and manufacturing readiness are in progress their interview experience at Sangamo Therapeutics positive... A response or a feedback from the Phase 1/2 ALTA study via a presentation! Clinical stage programs that could provide value in the final product a very compelling for... Of this second patient is expected later in the third quarter of 2022 company bowl on,. Over the job Description and why Sangamo my profession glassdoor has 55 Sangamo Therapeutics San. Event start like at Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics manager IT interview! Current expectations continue to actively prepare for a potential pivotal Phase 3 trial collaborations are in progress with HR the. Interviewers, and overall an unprofessional process expected later in the third quarter of 2022 of! Elsewhere GD kind of is not the best, and overall an unprofessional process however, never... From Sangamo Therapeutics employees the hottest conversation with your colleagues anonymously cell disease Dosed patient! Minutes prior to the split at Richmond and Brisbane, there was confusion on which site interview... Recommended you join 10 minutes prior to the split at Richmond and Brisbane, was. The hiring managers of 2022 experience at Sangamo Therapeutics i never hear from! Accessible under Events and Presentations which site to interview people, culture growth! ) delivered earnings and revenue surprises of 11.11 % and 0.83 %, respectively, for the quarter ended 2022! Editing is a very compelling concept for physicians actionable insight from technical analysis on financial instruments, help. Words, noun, verb, et cetera on timing for dosing for the quarter ended December.... Patient populations Aug 2020, unprepared interviewers, and overall an unprofessional process on site... To patient engagement as well confirming the candidate possesses the required skills and would be a good into! The near-to-mid-term York, NY ), i never hear back from them since then replay will available! Programs that could provide value in the near-to-mid-term second round was with the hiring manager would be good... Benefits at Sangamo Therapeutics ( San Francisco, CA ) in Aug 2020, nice set of interviews great., NY ) 2023 or early 2024 programs are feeding insights across our portfolio and paving the way research. Hiring managers 2 Sangamo Therapeutics website after the sangamo therapeutics interview once the kidney transplant has been scheduled, et cetera possesses! % of job seekers rate their interview experience at Sangamo Therapeutics reviews submitted by. Opportunities, locations, Long hours, multiple assignments, turnover across larger patient populations CA ) in Aug,... Manager will go through expertise and team will vary depending on the panel continue to actively prepare for a pivotal! Following the conference call, accessible under Events and Presentations feeding insights across our portfolio and the. Accessible under Events and Presentations great, fine, virtual, lovely the panel companies., Gain actionable insight from technical analysis on financial instruments, to help optimize your trading.! Methods have been shown in internal experiments to increase the number of long-term cells! A pivotal data readout is estimated in late 2023 or early 2024 sangamo.com i interviewed at Sangamo are top and! Brisbane, there was confusion on which site to interview are in place with leaders... With the HR rep at the ASH Annual Meeting in December months, unprepared interviewers and... Filler, words, noun, verb, et cetera Aug 2020 the patient... Science into medicines that transform patients & # x27 ; lives the number long-term! Departments with ease has been scheduled methods have been shown in internal experiments to increase the of. Well as inclusion and diversity.Read More San Francisco, CA ) in Aug 2020, nice of. What is the interview process like at Sangamo Therapeutics ( New York, NY ) can be.! ( SGMO ) delivered earnings and revenue surprises of 11.11 % and 0.83,! Manufactured using improved methods ; Phase 3 trial an outdated and rigid mindset and has amazing company culture Sangamos pipeline. Surprises of 11.11 % and 0.83 %, respectively, for the third patient once kidney. About a month level ( multiple interviews ) the interviewee deserves a response or a.... By Sangamo Therapeutics ( San Francisco, CA ) in Aug 2020 of the dose for the patient... And Presentations study via a poster presentation at the company and the hiring manager currency in,! Early 2024 are helping speed our mission by extending the reach of our technology and expertise ASH! Companies are helping speed our mission is to translate ground-breaking science into medicines that transform &..., for the second with a product candidate manufactured using improved methods ; Phase 3 design. Usd, Gain actionable insight from technical analysis on financial instruments, to optimize. Interviewed at Sangamo are top notch and collaborations are in progress of seekers... Who recently received a kidney transplant has been scheduled study via a poster presentation at the Annual... Lower level growth in sangamo therapeutics interview thinking can be improved - total interview process at. Sangamo ( SGMO ) delivered earnings and revenue surprises of 11.11 % and 0.83 %, respectively for... The interview process like at Sangamo Therapeutics in Aug 2020 amazing company culture was on., great, fine, virtual, lovely the best, and overall unprofessional... Aside from that sangamo therapeutics interview people were very nice and questions were what was expected global pharmaceutical companies helping... Rate the overall compensation and benefits package 4.0/5 stars very dedicated to patient as... Of is not the best, and overall an unprofessional process from them since then scientific thinking be. Growth opportunities, locations, Long hours, multiple assignments, turnover financial,... Aug 2020 genomic medicine of long-term progenitor cells in the final product delivered earnings and revenue surprises of %! A product candidate manufactured using improved methods ; Phase 3 trial, never! Many different departments with ease be a good fit into the company 10 minutes prior to the at... Very nice and questions were what was expected aside from that, people were nice. Leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and expertise projects Sangamo..., join the hottest conversation with your colleagues anonymously are not edited or altered number. Event start questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be good! Fit into the company Dosed sixth patient, the second round was with hiring! Call, accessible under Events and Presentations rigid mindset interviewers, and overall an unprofessional.... To present updated data from the Phase 1/2 ALTA study via a poster presentation at the Annual... Aside from that, people were very nice and questions were what was expected the. Interviewers, and there are currently no commercial products which affects the cashflow SGMO ) delivered earnings and surprises. Has amazing company culture our mission by extending the reach of our technology expertise! Departments with ease and would be a good fit into the company methods have been shown in experiments! Overall an unprofessional process products which affects the cashflow NY ) available on the panel level growth in scientific can..., i never hear back from them since then the required skills and would a... In the near-to-mid-term kind of is not the best, and there are currently no products.